Early insight,from a cheek swab.
Revealia reads mRNA signals of inflammation linked to breast cancer, from a sample you collect at home.
Revealia Breast is investigational and has not been cleared or approved by the FDA.
Revealia reads mRNA signals of inflammation linked to breast cancer, from a sample you collect at home.
Revealia Breast is investigational and has not been cleared or approved by the FDA.
Chronic inflammation is linked to more than half of all deaths worldwide, including from cancer and heart disease. Its signals are written in messenger RNA, the molecules your cells use to act on their genes.
Revealia captures that activity from the inside of your cheek. No needles, no imaging, no clinic visit to give a sample.
Inflammatory genes in our proprietary mRNA biomarker panel
Patient samples collected in our IRB-approved research program
U.S. clinical sites contributing samples
Sensitivity in our preliminary breast cancer analysis
Preliminary analysis of 249 samples (136 confirmed breast cancer, 113 controls) using our 48-gene panel and ensemble machine learning: sensitivity about 92%, specificity 54%, negative predictive value 86%. Results have not been reviewed by the FDA.
Ordered through your healthcare provider or a partner program, the kit comes to your door and goes back by mail.
A gentle swab of the inside of your cheek collects the cells we analyze. The sample travels back to the lab by mail.
Your sample is sequenced in a CLIA-certified laboratory and read against our 48-gene inflammation panel.
Certified genetic counselors walk you through your results, together with your own doctor.
Everything you need arrives in one box, with return shipping included to the laboratory.
Our platform pairs non-invasive collection with next-generation sequencing and ensemble machine-learning models. From our 48-gene panel we evaluated about 12.2 million gene combinations to arrive at a six-gene signature specific to breast cancer.
Gene combinations evaluated to build the breast signature
Genes in our proprietary breast cancer mRNA signature
Patent applications pending across key global jurisdictions
| Breast | Our lead test, Revealia Breast, built on preliminary multi-site validation. | Lead program |
| Lung, ovarian, pancreatic | Observational studies of about 600 participants approved by an IRB. | In development |
| Bladder, colorectal | Samples already collected in our multi-site research program. | Research |
| Beyond cancer | Inflammation-driven cardiovascular, neurodegenerative and metabolic disease. | Longer term |
Revealia reaches patients through the people they already trust, offered as a laboratory developed test in CLIA-certified, CAP-accredited labs.
Order within existing clinical workflows, referral pathways and telemedicine visits.
Run Revealia Breast with our proprietary algorithm, or refer samples to our affiliated lab.
Offer earlier insight to members, where late-stage care costs the most.
Certified counselors are built into ordering and results, in step with the patient's doctor.
Revealia is developed by Ludwig Enterprises, Inc., a genomics company focused on inflammation-related chronic disease.
Join the waitlist for launch updates, or talk to our team about bringing Revealia to your patients.